First Indian patent approval for Episurf Medical
The Indian patent office Intellectual Property India has reported that Episurf Medical (NASDAQ: EPIS B) has received its first granted patent in India. The patent, entitled “Surgical kit for cartilage repair comprising implant and a set of tools”, has a focus on Episurf Medical’s individualised Episealer® Femoral Twin joint implant and its design process.
“This patent forms a part of our global IP protection for the appreciated Episealer® Twin technology. This first approval in India comes very timely as we currently have commercial activities ongoing in the Indian market”, comments Katarina Flodström, COO, Episurf Medical.
CisionBlockPro\Cision\FeedItem Object
(
[HtmlCompanyInformation:protected] => <p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><strong><span style="font-size:10pt">About Episurf Medical</span></strong></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><em>Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.</em></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><span style="font-family:arial,helvetica,sans-serif; font-size:10pt"><em>This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14:00 CEST on 5 April 2022.</em></span></p>
[HtmlContact:protected] => <p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><strong><span style="font-size: 10pt; font-family: arial,helvetica,sans-serif;">For more information, please contact:</span></strong></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">Pål Ryfors, CEO, Episurf Medical<br /></span><span style="font-size: 10pt; font-family: arial,helvetica,sans-serif;">Tel:</span><span style="font-size: 10pt;">+46 (0) 709 62 36 69<br /></span><span style="font-size: 10pt;">Email: </span><a href="mailto:pal.ryfors@episurf.com">pal.ryfors@episurf.com</a></p>
[HtmlTitle:protected] => <h1 style="line-height:120%;"><span style="font-family:arial,helvetica,sans-serif"><strong>First Indian patent approval for Episurf Medical</strong></span></h1>
[HtmlHeader:protected] =>
[HtmlIntro:protected] =>
[Body:protected] => The Indian patent office Intellectual Property India has reported that Episurf Medical (NASDAQ: EPIS B) has received its first granted patent in India. The patent, entitled “Surgical kit for cartilage repair comprising implant and a set of tools”, has a focus on Episurf Medical’s individualised Episealer® Femoral Twin joint implant and its design process.
"This patent forms a part of our global IP protection for the appreciated Episealer® Twin technology. This first approval in India comes very timely as we currently have commercial activities ongoing in the Indian market”, comments Katarina Flodström, COO, Episurf Medical.
[HtmlBody:protected] => <p style="margin-bottom:10px;margin-top:12px"><span><span style="font-size:11pt"><span><span style="font-family:arial,helvetica,sans-serif">The Indian patent office Intellectual Property India has reported that Episurf Medical (NASDAQ: EPIS B) has received its first granted patent in India. The patent, entitled “<em>Surgical kit for cartilage repair comprising implant and a set of tools”</em>, <span>has a focus on Episurf Medical’s individualised Episealer</span><span>®</span><span> Femoral Twin joint implant and its design process</span>. </span></span></span></span></p>
<p style="margin-bottom:10px"><span><span style="font-size:11pt"><span><span style="font-family:arial,helvetica,sans-serif"><em>"</em><em><span>This patent forms a part of our global IP protection for the appreciated Episealer</span></em><em><span>®</span></em><em><span> Twin technology. This first approval in India</span></em><em> </em><em><span>comes </span></em><em>very timely as we currently have commercial activities ongoing in the Indian market</em>”, comments Katarina Flodström, COO, Episurf Medical.</span></span></span></span></p>
[ServiceCategories:protected] => Array
(
[0] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => EU Transparency SE
[Name:protected] => SeFsaCategoryCode
[Value:protected] => S6
)
[1] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => OMX Filing (OMX CNS)
[Name:protected] => OMX CategoryCode
[Value:protected] => 428
)
[2] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Twitter
[Name:protected] => Twitter
[Value:protected] => 9341
)
[3] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => LinkedIn
[Name:protected] => LinkedIn
[Value:protected] => 12311
)
[4] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Facebook
[Name:protected] => Facebook
[Value:protected] => 14035
)
)
[LogoUrl:protected] => https://mb.cision.com/Public/14691/logo/96c29c854b230ac3_org.png
[CompanyInformation:protected] => About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14:00 CEST on 5 April 2022.
[Contact:protected] => For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
[Header:protected] =>
[Keywords:protected] => Array
(
[0] => Episurf Medical
[1] => EpiSurf
[2] => Episealer
)
[QuickFacts:protected] => Array
(
)
[Categories:protected] => Array
(
)
[Videos:protected] => Array
(
)
[Files:protected] => Array
(
[0] => CisionBlockPro\Cision\File Object
(
[IsMain:protected] => 1
[MediaType:protected] => File
[Url:protected] => https://mb.cision.com/Main/14691/3540202/1559842.pdf
[FileName:protected] => wkr0006.pdf
[Title:protected] => First Indian patent approval for Episurf Medical
[Description:protected] => First Indian patent approval for Episurf Medical
[CreateDate:protected] => 2022-04-05T12:00:08.407Z
[Keywords:protected] => Array
(
)
[Extension:protected] => pdf
)
)
[Quotes:protected] => Array
(
)
[ExternalLinks:protected] => Array
(
)
[EmbeddedItems:protected] => Array
(
)
[Id:protected] => 4230303
[EncryptedId:protected] => 0A74CB2346AC82C7
[IsRegulatory:protected] => 1
[PublishDate:protected] => 2022-04-05T12:00:00Z
[LastChangeDate:protected] => 2022-04-05T12:00:08.39Z
[Title:protected] => First Indian patent approval for Episurf Medical
[Intro:protected] =>
[IptcCode:protected] => 04016003
[InformationType:protected] => PRM
[LanguageCode:protected] => en
[CountryCode:protected] => se
[CanonicalUrl:protected] =>
[CisionWireUrl:protected] => https://news.cision.com/episurf/r/first-indian-patent-approval-for-episurf-medical,c3540202
[LanguageVersions:protected] => Array
(
[0] => CisionBlockPro\Cision\LanguageVersion Object
(
[Code:protected] => sv
[ReleaseId:protected] => 4230301
)
)
[Images:protected] => Array
(
)
[Tickers:protected] => Array
(
[0] => stdClass Object
(
[Symbol] => EPIS B
[ISIN] => SE0003491562
[PrimaryListing] => 1
[IsShare] => 1
[MarketPlaceSymbol] => STO
[MarketPlaceName] => Stockholmsbörsen
[MarketPlaceBloombergCode] => SS
[MarketPlaceMarketWireCode] => OMX
[MarketPlaceIsRegulated] => 1
[MarketPlaceCountryCode] => SE
)
)
)